BICO Group AB
STO:BICO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
34.02
69.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
BICO Group AB
BICO Group AB
Cost of Revenue
BICO Group AB
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BICO Group AB
STO:BICO
|
Cost of Revenue
-kr1.1B
|
CAGR 3-Years
-75%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
AddLife AB
STO:ALIF B
|
Cost of Revenue
-kr6B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
|
Biotage AB
STO:BIOT
|
Cost of Revenue
-kr794m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-14%
|
|
|
G
|
Genovis AB
STO:GENO
|
Cost of Revenue
-kr45.2m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-64%
|
CAGR 10-Years
-12%
|
|
|
MedCap AB (publ)
STO:MCAP
|
Cost of Revenue
-kr954.9m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-4%
|
|
|
M
|
Magle Chemoswed Holding AB
STO:MAGLE
|
Cost of Revenue
-kr16.5m
|
CAGR 3-Years
18%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
BICO Group AB
Glance View
BICO Group AB is a bioconvergence company, which engages in the provision of technologies, products, and services to create, understand and master biology. The company is headquartered in Goeteborg, Vastra Gotalands and currently employs 890 full-time employees. The company went IPO on 2016-11-03. The firm focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The firm develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.
See Also
What is BICO Group AB's Cost of Revenue?
Cost of Revenue
-1.1B
SEK
Based on the financial report for Dec 31, 2023, BICO Group AB's Cost of Revenue amounts to -1.1B SEK.
What is BICO Group AB's Cost of Revenue growth rate?
Cost of Revenue CAGR 3Y
-75%
Over the last year, the Cost of Revenue growth was -4%. The average annual Cost of Revenue growth rates for BICO Group AB have been -75% over the past three years .
You don't have any saved screeners yet
